Replies to post #394570 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Aduhelm was approved on a surrogate endpoint biomarker showing amyloid plaque reduction seen as a reasonably likely inferred clinical benefit.

The advisory committee voted overwhelmingly against that idea, but the FDA did not want to make a type 2 error.